Cytostatics and monoclonal antibodies are central pillars in tumor treatment. The basic substances are produced by the pharmaceutical industry, while the patient-specific preparation or dosage is carried out in specialized pharmacies or hospitals.
Due to their mechanism of action, the cytostatic drugs used are carcinogenic, mutagenic and/or reprotoxic (CMR: carcinogenic, mutagenic and reprotoxic). Compliance with Good Manufacturing Practices (GMP) or equivalent national guidelines is essential to ensure good product quality and the protection of personnel and the environment. In addition to safe handling techniques, validated cleaning procedures are also required.
Possible hazards from cytostatic drug residues
In the "MEWIP" research project 2, the contamination of the working environment with cytostatic drugs was determined by repeated sampling of selected surfaces. Carry-over and contamination with cytostatic agents was detected on a wide variety of surfaces. They can pose a health risk on keyboards and telephones, in the laboratory, in storage and disposal rooms, in patient toilets, in ward rooms and corridors.
How perform® sterile mucasol protects against contact with harmful cytostatics
The newly developed perform® sterile mucasol enables a safe workplace thanks to its proven high effectiveness in cleaning and thus reduces risks when handling cytostatic drugs - especially in sterile areas A and B. The effectiveness of the product has been proven in a study commissioned by schülke from the Institute for Environment & Energy, Technology & Analytics e. V. (IUTA). To determine the cleaning performance, test surfaces were first contaminated with a defined concentration of ten common cytostatics. After the solvent had dried, the surfaces were cleaned with different wipes, cleaning solutions and quantities of cleaning solvent, depending on the study design. The result: perform® sterile mucasol showed excellent cleaning results even when used once with perform® sterile mixed dry wipes. In a combined cleaning with perform® sterile mucasol and subsequent disinfection with perform sterile alcohol IPA, all 10 tested cytostatics were cleaned to 93.6 % - 99.9 %.
Product information perform® sterile mucasol
Sterile working solution with 2 % perform classic concentrate mucasol®; alkaline cleaner (pH approx. 11.6); cleaning of common cytostatic drugs, proven by a study with the IUTA1; available in 500 ml and 1 l bottles, double repackaged for safe introduction into cleanroom zones; with tested bag-in-bottle system for maintaining sterility after opening: Click here for more information.
Sources:
1 Institut für Umwelt & Energie, Technik & Analytik e. V. - IUTA-Report of analysis No. 23/449: cleaning validation study of perform® sterile mucasol for cytostatic drugs / Institut für Umwelt & Energie, Technik & Analytik e. V. - IUTA-Report of analysis No. 23/449: cleaning validation study of perform® sterile mucasol for cytostatic drugs / Institut für Umwelt & Energie, Technik & Analytik e. V. - IUTA-Report of analysis No. 23/718: cleaning validation study of perform® sterile mucasol for monoclonal antibodies
2 Monitoring effect study for wipe samples in pharmacies, BGW & Institut für Energie- und Umwelttechnik e. V., 2008
Schülke & Mayr GmbH (schülke)
Schülke & Mayr GmbH, headquartered in Norderstedt near Hamburg, has been a leading global provider in the field of infection prevention and control for almost 135 years. Infectious agents know no borders - this has always been true and is all the more important in today's globalized world. Committed to the mission "We protect lives worldwide", schülke actively contributes to the safety and health protection of people with its strategic business areas Healthcare, Over the Counter (OTC), Life Sciences and Direct Patient Care. With strong brands such as octenisept®, kodan®, desderman® and microshield®, schülke is one of the international market leaders in the field of wound and mucous membrane antiseptics as well as hand and surface disinfection in German hospitals. In more than 80 countries around the world, people rely on schülke products every day. With its wide range of high-quality and innovative products, expert advice and reliable service, schülke offers holistic concepts for infection treatment and control in professional healthcare, for end users and the pharmaceutical sector. schülke has more than 1,100 dedicated employees, over 20 subsidiaries and three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma). In 2022 alone, schülke contributed to protecting patients and healthcare professionals in hospitals from infections with almost three billion product applications.
More about schülke at: www.schuelke.com